Atossa Genetics (ATOS)
(Real Time Quote from BATS)
$0.80 USD
-0.01 (-0.62%)
Updated Aug 6, 2025 12:04 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATOS 0.80 -0.01(-0.62%)
Will ATOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATOS
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
Other News for ATOS
Atossa Therapeutics reports 'positive' FDA feedback regarding (Z)-endoxifen
Atossa Therapeutics (ATOS) Gains FDA Support for Breast Cancer Drug Trial
Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen ...
Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)
Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Target | ATOS Stock News